Triglycerides as vascular risk factors: New epidemiologic insights

Current Opinion in Cardiology

Volumn 24, Issue 4, 2009, Pages 345-350

  Kannel, William B ^a   Vasan, Ramachandran S ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cardiovascular disease; Epidemiology; Risk factors; Triglycerides

Indexed keywords

ATORVASTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN; PRAVASTATIN; TRIACYLGLYCEROL;

ATHEROGENESIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DRUG MEGADOSE; HUMAN; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TRIACYLGLYCEROL BLOOD LEVEL; CARDIOVASCULAR DISEASES; CORONARY ARTERY DISEASE; HYPERTRIGLYCERIDEMIA; RISK FACTOR; UNITED STATES;

CARDIOVASCULAR DISEASES; CORONARY ARTERY DISEASE; HUMANS; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; RISK FACTORS; TRIGLYCERIDES; UNITED STATES;

EID: 67651160487     PISSN: 02684705     EISSN: None     Source Type: Journal    
DOI: 10.1097/HCO.0b013e32832c1284     Document Type: Review

References (46)

1. Moreton JR. Atherosclerosis and alimentary hyperlipemia. Science 1947; 106:190-191.
2. Brinton EA, Nanjee MN, Hopkins PN. Triglyceride-rich lipoprotein remnant levels and metabolism: time to adopt these orphan risk factors? J Am Coll Cardiol 2004; 43:2233-2235.
3. Williams KJ. Molecular processes that handle - and mishandle - dietary lipids. J Clin Invest 2008; 118:3247-3259. A review article that details pathophysiological processes contributing to dyslipidemia with a focus on molecular events involved in lipid transport from the gut to the periphery and the liver.
4. Patsch JR, Miesenbock G, Hopferwieser T, et al. Relation of triglyceride metabolism and coronary artery disease. Studies in the postprandial state. Arterioscler Thromb 1992; 12:1336-1345.
5. Nakamura T, Takano H, Umetani K, et al. Remnant lipoproteinemia is a risk factor for endothelial vasomotor dysfunction and coronary artery disease in metabolic syndrome. Atherosclerosis 2005; 181:321-327. (Pubitemid 41019613)
6. Nordestgaard BG, Wootton R, Lewis B. Selective retention of VLDL, IDL, and LDL in the arterial intima of genetically hyperlipidemic rabbits in vivo: molecular size as a determinant of fractional loss from the intima-inner media. Arterioscler Thromb Vasc Biol 1995; 15:534-542.
7. Shaikh M, Wootton R, Nordestgaard BG, et al. Quantitative studies of transfer in vivo of low density, Sf 12-60, and Sf 60-400 lipoproteins between plasma and arterial intima in humans. Arterioscler Thromb 1991; 11:569-577.
8. Tabas I, Williams KJ, Boren J. Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications. Circulation 2007; 116:1832-1844. (Pubitemid 350287108)
9. Rapp JH, Lespine A, Hamilton RL, et al. Triglyceride-rich lipoproteins isolated by selected-affinity antiapolipoprotein B immunosorption from human atherosclerotic plaque. Arterioscler Thromb 1994; 14:1767-1774. (Pubitemid 2164784)
10. Austin MA, King MC, Vranizan KM, Krauss RM. Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk. Circulation 1990; 82:495-506.
11. Berneis KK, Krauss RM. Metabolic origins and clinical significance of LDL heterogeneity. J Lipid Res 2002; 43:1363-1379.
12. Tan KC, Cooper MB, Ling KL, et al. Fasting and postprandial determinants for the occurrence of small dense LDL species in noninsulin-dependent diabetic patients with and without hypertriglyceridaemia: the involvement of insulin, insulin precursor species and insulin resistance. Atherosclerosis 1995; 113:273-287.
13. Otvos JD, Collins D, Freedman DS, et al. Low-density lipoprotein and highdensity lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the veterans affairs high-density lipoprotein intervention trial. Circulation 2006; 113:1556-1563. (Pubitemid 43739414)
14. Rashid S, Watanabe T, Sakaue T, Lewis GF. Mechanisms of HDL lowering in insulin resistant, hypertriglyceridemic states: the combined effect of HDL triglyceride enrichment and elevated hepatic lipase activity. Clin Biochem 2003; 36:421-429. (Pubitemid 37083556)
15. Ji J, Watts GF, Johnson AG, et al. High-density lipoprotein (hdl) transport in the metabolic syndrome: application of a new model for HDL particle kinetics. J Clin Endocrinol Metab 2006; 91:973-979. (Pubitemid 43357768)
16. Chan DC, Nguyen MN, Watts GF, Barrett PH. Plasma apolipoprotein C-III transport in centrally obese men: associations with very low-density lipoprotein apolipoprotein B and high-density lipoprotein apolipoprotein A-I metabolism. J Clin Endocrinol Metab 2008; 93:557-564.
17. Adiels M, Taskinen MR, Packard C, et al. Overproduction of large VLDL particles is driven by increased liver fat content in man. Diabetologia 2006; 49:755-765. (Pubitemid 43357551)
18. Matikainen N, Manttari S,Westerbacka J, et al. Postprandial lipemia associates with liver fat content. J Clin Endocrinol Metab 2007; 92:3052-3059. (Pubitemid 47236370)
19. Brinton EA, Eisenberg S, Breslow JL. Increased apo A-I and apo A-II fractional catabolic rate in patients with low high density lipoprotein- cholesterol levels with or without hypertriglyceridemia. J Clin Invest 1991; 87:536-544.
20. Das DK. Cardioprotection with high-density lipoproteins: fact or fiction? Circ Res 2003; 92:258-260.
21. Kathiresan S, Willer CJ, Peloso GM, et al. Common variants at 30 loci contribute to polygenic dyslipidemia. Nat Genet 2009; 41:56-65.
22. Kathiresan S, Melander O, Guiducci C, et al. Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans. Nat Genet 2008; 40:189-197. (Pubitemid 351171402)
23. Carroll MD, Lacher DA, Sorlie PD, et al. Trends in serum lipids and lipoproteins of adults, 1960-2002. JAMA 2005; 294:1773-1781.
24. Ghandehari H, Kamal-Bahl S, Wong ND. Prevalence and extent of dyslipidemia and recommended lipid levels in US adults with and without cardiovascular comorbidities: the National Health and Nutrition Examination Survey 2003-2004. Am Heart J 2008; 156:112-119.
25. Trends in lipid fractions and antidyslipidemic use among US adults: findings from the National Health and Nutrition Examination Survey II, III, and 1999- 2006. Circulation 2009; 118:S470.
26. Sarwar N, Danesh J, Eiriksdottir G, et al. Triglycerides and the risk of coronary heart disease: 10 158 incident cases among 262 525 participants in 29 western prospective studies. Circulation 2007; 115:450-458.
27. Asia Pacific Cohort Studies Collaboration: serum triglycerides as a risk factor for cardiovascular diseases in the Asia-Pacific Region. Circulation 2004; 110:2678-2686. (Pubitemid 39453019)
28. Tirosh A, Rudich A, Shochat T, et al. Changes in triglyceride levels and risk for coronary heart disease in young men. Ann Intern Med 2007; 147:377-385. (Pubitemid 351664538)
29. Albrink MJ, Man EB. Serum triglycerides in coronary artery disease. Arch Intern Med 1959; 103:4-8.
30. Fager G, Wiklund O, Olofsson SO, et al. Multivariate analyses of serum apolipoproteins and risk factors in relation to acute myocardial infarction. Arteriosclerosis 1981; 1:273-279. (Pubitemid 12229735)
31. Goldstein JL, Hazzard WR, Schrott HG, et al. Hyperlipidemia in coronary heart disease. I: lipid levels in 500 survivors of myocardial infarction. J Clin Invest 1973; 52:1533-1543.
32. Bainton D, Miller NE, Bolton CH, et al. Plasma triglyceride and high density lipoprotein cholesterol as predictors of ischaemic heart disease in British men: the Caerphilly and Speedwell Collaborative Heart Disease Studies. Br Heart J 1992; 68:60-66.
33. Austin MA. Plasma triglyceride and coronary heart disease. Arterioscler Thromb 1991; 11:2-14.
34. Zilversmit DB. Atherogenesis: a postprandial phenomenon. Circulation 1979; 60:473-485.
35. Abdel-Maksoud MF, Hokanson JE. The complex role of triglycerides in cardiovascular disease. Semin Vasc Med 2002; 2:325-333.
36. Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk 1996; 3:213-219.
37. Bansal S, Buring JE, Rifai N, et al. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA 2007; 298:309-316. (Pubitemid 47080485)
38. Freiberg JJ, Tybjaerg-Hansen A, Jensen JS, Nordestgaard BG. Nonfasting triglycerides and risk of ischemic stroke in the general population. JAMA 2008; 300:2142-2152.
39. Langsted A, Freiberg JJ, Nordestgaard BG. Fasting and nonfasting lipid levels: influence of normal food intake on lipids, lipoproteins, apolipoproteins, and cardiovascular risk prediction. Circulation 2008; 118:2047-2056.
40. Mora S, Rifai N, Buring JE, Ridker PM. Fasting compared with nonfasting lipids and apolipoproteins for predicting incident cardiovascular events. Circulation 2008; 118:993-1001.
41. Nordestgaard BG, Benn M, Schnohr P, Tybjaerg-Hansen A. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA 2007; 298:299-308. (Pubitemid 47080484)
42. Kannel WB, Vasan RS, Keyes MJ, et al. Usefulness of the triglyceride-highdensity lipoprotein versus the cholesterol-high-density lipoprotein ratio for predicting insulin resistance and cardiometabolic risk (from the Framingham Offspring Cohort). Am J Cardiol 2008; 101:497-501. A recent Framingham study investigation of the predictive utility of blood lipids and their ratios (including total/HDL-C) for detecting insulin resistance and predicting its CHD hazard, which challenges the notion that triglyceride/ HDL ratio is a superior indicator of insulin resistance and its CHD consequences.
43. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285:2486-2497.
44. Ridker PM, Rifai N, Cook NR, et al. Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women. JAMA 2005; 294:326-333. (Pubitemid 41043776)
45. Brunzell JD, Davidson M, Furberg CD, et al. Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation. J Am Coll Cardiol 2008; 51:1512-1524.
46. Miller M, Cannon CP, Murphy SA, et al. Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial. J Am Coll Cardiol 2008; 51:724-730. (Pubitemid 351221217)